Fang X, Wang H, Han D, Xie E, Yang X, Wei J, et al
Retrieved from: Hjalmarsdottir, F
Representative domains include: Gastrointestinal and hepatic models: Protection against ulcers, leaky gut, IBSlike symptoms, Crohntype inflammation, and toxic liver injury (e.g., CCl4, NSAID, and alcohol models), with improved mucosal healing and barrier integrity
Cagrilintide, the second generation (2020s) Novo Nordisk took the Pramlintide concept and applied the same half-life extension strategy that they used with Semaglutide: Kept the proline substitutions (anti-amyloid) Added a C20 fatty diacid via a -Glu linker to a lysine residue, albumin binding Additionally stabilized the N- and C-terminal positions Result: Cagrilintide with a half-life of 6.6 days (vs 50 minutes for Pramlintide)